Skip to main content

Quanterix Invests in ImmunArray, Gains Access to Brain Injury Biomarker Portfolio

NEW YORK (GenomeWeb) – Quanterix today announced a strategic investment in ImmunArray, a move that could strengthen each company's efforts in addressing neurodegenerative disease diagnostics.

Under the terms of the agreement, Lexington, Massachusetts-based Quanterix will gain access to ImmunArray's biomarker portfolio for traumatic brain injury and add select biomarkers to its multiplex panel for neurology research. ImmunArray, based in both Israel and Virginia, will in turn gain access to Quantertix's Simoa single-molecule array technology.

Financial and other details of the deal were not disclosed.

ImmunArray has its own biomarker analysis platform, the iChip antibody-detecting microarray system, for which it has developed multiplex panels for clinical diagnostics.

Both companies won GE and National Football League "Head Health Challenge" grants in 2014.

"ImmunArray has built an attractive portfolio of brain health biomarkers that nicely complement our existing menu of assays," Quanterix CEO Kevin Hrusovsky said in a statement. "We are also delighted that they will utilize our Simoa technology to further develop their portfolio for clinical utility."

ImmunArray CEO Donna Edmonds added that the collaboration would allow the companies to provide a broad portfolio of biomarker and panels for research on detection and diagnosis of acute and chronic traumatic brain injury and other neurodegenerative diseases.

The deal is the latest investment for privately-held ImmunArray. In July, the firm announced a $10 million Series B investment from Exigent Capital.